



# PTEN MEN



The medical management guidelines from the National Comprehensive Cancer Network (NCCN) for patients with a PTEN pathogenic / likely pathogenic variant are listed in this document.


This overview is for informational purposes and does not constitute a personalised recommendation. **Recommended options may vary based on your personal and family history. Access to some options may also vary from one medical center to another.** The specific references should be consulted for more details before developing a treatment plan.

In addition, the information available on hereditary cancer susceptibility genes is constantly evolving and **it is recommended to check this information annually as the management guidelines may change in the future.**

## LIFETIME ASSOCIATED RISKS

(UP TO AGE 75)

PTEN Hamartoma Tumor syndrome is rare and it includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related Proteus syndrome and Proteus-like syndrome. An individual who is a carrier of a PTEN pathogenic / likely pathogenic variant has an elevated risk of developing benign tumors (called hamartomas) as well as certain cancers during their lifetime.



### OTHER TYPES OF CANCER

Preliminary evidence suggests a possible increased risk for other types of cancer, including central nervous syndrome cancer.

However, specific risks have not been established and more research is needed to confirm these findings.

#### References:

Daly M et coll. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 2.2021. November 20, 2020. <http://www.nccn.org>

Eng C. PTEN Hamartoma Tumor Syndrome. 2001 Nov 29 [Updated 2016 Jun 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1488/>



# PTEN MEN



**THYROID CANCER** **KIDNEY CANCER**  
**COLORECTAL CANCER** **OTHER TYPES OF CANCER**  
**SCREENING**

**STARTING AT AGE 7**

- THYROID ULTRASOUND EVERY YEAR

7

18

**STARTING AT AGE 18**  
 OR 5 YEARS BEFORE THE EARLIEST CANCER DIAGNOSIS IN THE FAMILY

- COMPREHENSIVE PHYSICAL EXAM, WITH PARTICULAR ATTENTION TO THYROID AND SKIN EXAM EVERY YEAR

35

**STARTING AT AGE 35**  
 OR 5-10 YEARS EARLIER THAN THE YOUNGEST COLORECTAL CANCER DIAGNOSIS IN THE FAMILY

- COLONOSCOPY EVERY 5 YEARS OR MORE FREQUENTLY BASED ON SYMPTOMS OR PRESENCE OF POLYPS

40

**STARTING AT AGE 40**  
 • CONSIDER RENAL ULTRASOUND EVERY 1-2 YEARS

**MELANOMA**  
**SCREENING**

CONSIDER REFERRAL TO A DERMATOLOGIST FOR WHOLE-BODY SKIN EXAMINATION AND EYE EXAM

**RISK REDUCTION**

- IT IS RECOMMENDED TO LIMIT EXPOSURE TO UV RADIATION BY AVOIDING EXCESSIVE SUN EXPOSURE, BY WEARING A HAT, SUNGLASSES AND LONG PROTECTIVE CLOTHES; BY APPLYING SUNSCREEN WITH A SUN PROTECTION FACTOR (SPF) OF 30 OR MORE; BY AVOIDING SUN TANNING BEDS AND LAMPS.
- REPORT TO YOUR HEALTHCARE PROVIDER ANY UNUSUAL OR CHANGES IN BEAUTY MARKS OR MOLES.

**OTHER TYPES OF CANCER**  
**SCREENING**

CONSIDER PSYCHOMOTOR ASSESSMENT IN CHILDREN AND BRAIN MRI IF THERE ARE SYMPTOMS.